将细胞(人胰腺细胞系,Mia PaCa-2,BxPC-3,AsPC-1,PANC-1,PL-45和正常胰腺导管上皮细胞,hTERT-HPNE细胞)接种到96孔板中(3000细胞/孔)一式三份。孵育过夜后,更换培养基并用I3C和/或NBMPR处理细胞24小时。再次更换培养基,并在存在或不存在相同浓度的I3C和/或NBMPR的情况下,在含有不同浓度的吉西他滨的培养基中培养细胞48小时。然后按照制造商的说明对细胞进行CellTiter 96 AQueous One Solution Cell Proliferation Assay(MTS)。在加入20μLMTS试剂/孔后2小时测量490nm处的吸光度[1]。
数据来源文献
[1]. Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80. [2]. Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194. [3]. Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18(2):198-206 [4]. Lou M, et al. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. J Biol Chem. 2017 Jun 2;292(22):9136-9149. [5]. Wang Y, et al. Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways. Chem Biol Interact. 2018 May 18;290:44-51.